Harrow Inc

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Apr 1, 2026TrialStudy Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

Mar 4, 2024FDAOlux — BYQLOVI

Jul 15, 2023TrialThe Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine

May 19, 2020FDAOlux — IMPEKLO

Nov 28, 2017FDAOlux — IMPOYZ

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

6 patent groups across drugs · Source: FDA Orange Book

DrugExpires

IlevroJan 31, 2027 Olux4 patentsAug 31, 2030 IlevroDec 1, 2030 IlevroMar 31, 2032 OluxMar 11, 2035 Olux2 patentsMay 9, 2036

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Natacyn — NATACYN

Application NDA050514 (NDA)

19852 events

FDADec 27

Olux — TEMOVATE

Application NDA019322 (NDA)

FDADec 27

Olux — TEMOVATE

Application NDA019323 (NDA)

19871 event

FDADec 31

Iopidine — IOPIDINE

Application NDA019779 (NDA)

19901 event

FDAFeb 22

Olux — TEMOVATE

Application NDA019966 (NDA)

19931 event

FDAJul 30

Iopidine — IOPIDINE

Application NDA020258 (NDA)

19943 events

FDADec 30

Vexol — VEXOL

Application NDA020474 (NDA)

FDAJun 17

Olux — TEMOVATE E

Application NDA020340 (NDA)

FDAApr 29

Olux — TEMOVATE

Application NDA020337 (NDA)

20001 event

FDAMay 26

Olux — OLUX

Application NDA021142 (NDA)

20031 event

FDAJul 24

Olux — CLOBEX

Application NDA021535 (NDA)

20041 event

FDAFeb 5

Olux — CLOBEX

Application NDA021644 (NDA)

20052 events

FDAOct 27

Olux — CLOBEX

Application NDA021835 (NDA)

FDAAug 19

Ilevro — NEVANAC

Application NDA021862 (NDA)

20071 event

FDAJan 12

Olux — OLUX E

Application NDA022013 (NDA)

20121 event

FDAOct 16

Ilevro — ILEVRO

Application NDA203491 (NDA)

20171 event

FDANov 28

Olux — IMPOYZ

Application NDA209483 (NDA)

20201 event

FDAMay 19

Olux — IMPEKLO

Application NDA213691 (NDA)

20241 event

FDAMar 4

Olux — BYQLOVI

Application NDA218158 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)